Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
6 hedge funds and large institutions have $1.68K invested in Unity Biotechnology in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 30 closing their positions.
14.83% less ownership
Funds ownership: 15% → 0.17% (-15%)
83% less funds holding
Funds holding: 35 → 6 (-29)
97% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 30
100% less capital invested
Capital invested by funds: $987K → $1.68K (-$986K)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$4.01K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$386K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$256K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$64.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$58.5K |
| 5 |
Renaissance Technologies
New York
|
-$37.8K |
UBX Hedge Fund Activity: Q3 2025 in Review
6 of the 7,642 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q3 2025, worth a combined $1.68K — down 100% from $987K a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of UBX and 1 opened new positions — a net loss of 29 holders — while 3 trimmed existing stakes and 0 added.
The largest buyer was XTX Topco, opening a new position worth an estimated $4.01K. The largest seller was Arch Venture Management, exiting entirely with an estimated $386K sold.
- 6 institutional investors held Unity Biotechnology (UBX) as of Q3 2025, down from 35 in Q2 2025.
- Funds reported $1.68K of Unity Biotechnology stock for Q3 2025, down 100% quarter-over-quarter.
- 1 fund opened new Unity Biotechnology positions in Q3 2025 and 30 closed out, a net change of -29 holders.
- The largest Unity Biotechnology buyer in Q3 2025 was XTX Topco, an estimated $4.01K added.
- The largest Unity Biotechnology seller in Q3 2025 was Arch Venture Management, an estimated $386K sold.
Based on aggregated 13F filings for Q3 2025.